BIOLOGICAL RESPONSE MODIFIERS ADVISORY COMMITTEE
November 16-17, 2000
Slides
FDA Introduction - Structural Characterization of Gene Transfer Vectors, Steven Bauer, PhD, CBER ppt html
DNA Sequencing of Viral Gene Therapy Vectors During Preclinical and Clinical Development, Louis Zumstein, PhD, Introgen Therapeutics Inc ppt html
FDA Introduction - Preclinical Animal Models in Gene Transfer Research, Anne Pilaro, PhD, CBER ppt html
FDA Introduction - Vector Classes with Potential for Long-Term Risks, Carolyn Wilson, PhD, CBER ppt html
Long-Term Follow-UP of Subjects in Gene Transfer Clinical Trials, Philippe Bishop, MD, CBER ppt html
FDA Introduction - Preclinical Considerations for Gene Transfer Clinical Trials: Vector Biodistribution, Mercedes Serabian, MS, CBER ppt html
Risk of Germ Line Transduction After Director Injection of Retroviral Vectors, Deborah Hurst, MD, Chiron Corp. ppt html